Brightsurf Science News and Current Science News Events
 
Email a Friend Send to a friend
Printer Friendly Print New study replicates association between genetic variation and antidepressant treatment response

New study replicates association between genetic variation and antidepressant treatment response

July 16, 2008

Pharmacogenetics, the study of genetic variation that influences an individual's response to drugs, is an important and growing focus in all of medical research, including psychiatry. It is a complex field, however, revealed by the lack of consistent and replicable findings across multiple studies, but some encouraging results are beginning to emerge. A new study scheduled for publication in the June 15th issue of Biological Psychiatry evaluated genetic markers in the treatment response of antidepressants and this work implicates the same markers as found in a prior trial.

Lekman and colleagues, using clinical data and DNA samples from the largest depression treatment study to date, the STAR*D study, compared individual treatment response (the reduction or remission of depressive symptoms) to individual genotypes. The researchers found that certain markers, or variations, in the FKBP5 gene are associated with treatment response to citalopram, a widely used antidepressant drug. In other words, patients with a particular genotype tended to respond better to the antidepressant treatment than others. Silvia Paddock, Ph.D., corresponding author on this article, further explains: "Our results are encouraging, because they support earlier findings by a German group implicating the same gene. It is promising to see the same genetic markers to be associated with response in hospitalized patients in the German study, as well as non-hospitalized patients in our study."




John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, explains some background of this important gene: "FKBP5 is a gene that codes for a protein that influences the molecular actions of a class of stress hormones, the glucocorticoids. In prior studies, variation in this gene was associated with the emergence of dissociative symptoms in traumatized children and PTSD symptoms in adults who had been maltreated as children." Childhood maltreatment has been previously reported to be a predictor of poor response to some antidepressants. Now that this current report has also implicated variation in the FKBP5 gene as related to antidepressant response, he adds that "we now need to close this apparent 'loop,' i.e., we need to understand how, at a molecular level and in the context of the developing brain, FKBP5 links childhood maltreatment and antidepressant response." Dr. Paddock agrees that further research is necessary, noting that it's needed "in order to confirm our results in further samples and understand the mechanism by which the genetic markers influence the chance of a depressed patient to respond to an antidepressant. This will, ultimately, allow us to develop new and better treatment strategies."

Elsevier



Related Antidepressant News Articles Antidepressant News and Current Antidepressant Events RSS Antidepressant News and Current Antidepressant Events RSS
Sex differences seen in response to common antidepressant
Women with depression may be much more likely than men to get relief from a commonly used, inexpensive antidepressant drug, a new national study finds. But many members of both sexes may find that it helps ease their depression symptoms.

Antidepressants in suicide prevention
Antidepressants are the cornerstone of treatment of depressive disorders in health care. Their efficacy in treating depression is undisputable, although it leaves room for improvement.

Potential new targets for antidepressant medications
The news about antidepressant medications over the past several years has been mixed. The bad news from large multicenter studies such as STAR*D is that current antidepressant medications are effective, but not as effective as one might hope. Thus, there is a significant need for new treatment mechanisms for depression.

Antidepressants may impair driving ability, new research finds
People taking prescription antidepressants appear to drive worse than people who aren't taking such drugs, and depressed people on antidepressants have even more trouble concentrating and reacting behind the wheel.

Study finds connections between genetics, brain activity and preference
A team of researchers from Massachusetts General Hospital (MGH) has used brain imaging, genetics and experimental psychology techniques to identify a connection between brain reward circuitry, a behavioral measurement of preference and a gene variant that appears to influence both.

Voluntary exercise does not appear to alleviate anxiety and depression
Voluntary physical activity does not appear to cause a reduction in anxiety and depression, but exercise and mood may be associated through a common genetic factor, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

N.Y. Research Team Discovers How Antidepressants and Cocaine Interact with Brain Cell Targets
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.

Use of sildenafil associated with improvement in antidepressant-related sexual dysfunction in women
Women with sexual dysfunction caused by the use of antidepressants experienced a reduction in adverse sexual effects with use of sildenafil, commonly known as the erectile dysfunction medication Viagra.

Study Shows Promising Results in Deep Brain Stimulation for Treatment-Resistant Depression
New data from a study of patients with treatment-resistant depression who underwent deep brain stimulation (DBS) in the subcallosal cingulate region (SCG or Cg25) of the brain shows that this intervention is generally safe and provides significant improvement in patients as early as one month after treatment. The patients also experienced continued and sustained improvement over time.

UNC study ties ending moderate drinking to depression
Scientific evidence has long suggested that moderate drinking offers some protection against heart disease, certain types of stroke and some forms of cancer.
More Antidepressant News Articles


Bipolar Disorder for Dummies
by Candida Fink, Joe Kraynak

Bipolar Disorder affects many more people than just the 2.5 million Americans who suffer from the disease. Like depression and other serious illnesses, bipolar disorder also affects spouses, partners, family members, friends and coworkers. And, according to the Child and Adolescent Bipolar Foundation, 150f children diagnosed with ADHD may actually be suffering from early-onset of Bipolar...



Tom Cruise: An Unauthorized Biography
by Andrew Morton

1992: Andrew Morton showed a Princess in a light we had never seen before--Diana: Her True Story became a #1 New York Times bestseller.1999: Andrew Morton revealed the young woman behind the blue dress--Monica’s Story was a #1 New York Times bestseller.January 15, 2008: Andrew Morton uncovers the true story of the biggest celebrity of our age. Everyone knows Tom Cruise---or at least...



The Serotonin Power Diet: Use Your Brain's Natural Chemistry to Cut Cravings, Curb Emotional Overeating, and Lose Weight (Hardcover)
by Nina Frusztajer Marquis, Judith J. Wurtman

Using this science-based plan, dieters will learn how to eat in order to boost serotonin, the brain chemical that shuts off appetite and turns on feelings of calm. This clinically tested program is also the first to offer antidepressant users an effective way to lose extra weight associated with their medication.The Serotonin Power Diet is based on more than 30 years of pioneering research at MIT...



Side Effects: A Prosecutor, a Whistleblower, and a Bestselling Antidepressant on Trial
by Alison Bass

As the mental health reporter for the Boston Globe, Alison Bass's front-page reporting on conflicts of interest in medical research stunned readers, and her series on sexual misconduct among psychiatrists earned a Pulitzer Prize nomination. Now she turns her investigative skills to a controversial case that exposed the increased suicide rates among adolescents taking antidepressants such as...



Listening to Prozac: The Landmark Book About Antidepressants and the Remaking of the Self, Revised Edition
by Peter D. Kramer

Psychiatrist Peter Kramer's book Listening to Prozac created a sensation when it was released in 1993, and it remains the most fascinating look at the new generation of antidepressants. Kramer found that the changes in brain chemistry brought about by Prozac had a wide variety of effects, often giving users greater feelings of self-worth and confidence, less sensitivity to social rejection,...



Natural Prozac: Learning to Release Your Body's Own Anti-Depressants
by Joel C. Robertson

Another book that seeks to help the depressed change their brain chemistry without medication, Natural Prozac divides such people into two types. "Satiation" types seek to boost their levels of the neurotransmitter serotonin to promote relaxation, calmness, and a sense of security, and often become uncomfortable in overly arousing situations. "Arousal" types, on the other hand, eat foods and...



Medicines for Mental Health: The Ultimate Guide to Psychiatric Medication
by Kevin PhD Thompson

A finalist in the National Indie Excellence 2008 book awards, this book was written for anyone who suffers from sexual dysfunction, depression, bipolar disorder, or schizophrenia (or cares for someone who does). Medicines for Mental Health is the first book to provide detailed and readable information about all psychiatric medications, and other medical treatments, for these mental illnesses....



The Anti-Depressant Fact Book: What Your Doctor Won't Tell You About Prozac, Zoloft, Paxil, Celexa, and Luvox
by Peter R. Breggin

Known as "the Ralph Nader of psychiatry," Dr. Peter Breggin has been the medical expert in countless court cases involving the use or misuse of psychoactive medications. This unusual position has given him unprecedented access to private pharmaceutical research and correspondence files, information from which informs this straight-talking guide to the most prescribed and controversial category of...



The Antidepressant Solution: A Step-by-Step Guide to Safely Overcoming Antidepressant Withdrawal, Dependence, and "Addiction"
by Joseph Glenmullen

With the FDA's warning that antidepressants may cause agitation, anxiety, hostility, and even violent or suicidal tendencies, these medications are at the forefront of national legal news. Harvard physician Joseph Glenmullen has led the charge to warn the public that antidepressants are overprescribed, underregulated, and, especially, misunderstood in their side and withdrawal effects. Now he...



Depression and Bipolar Disorder: Stahl's Essential Psychopharmacology, 3rd edition (Essential Psychopharmacology Series)
by Stephen M. Stahl

Essential. Trusted. Indispensable. Stahl's Essential Psychopharmacology has established itself as the preeminent source of education and information in its field. This much-expanded third edition relies on advances in neurobiology and recent clinical developments to explain the concepts underlying drug treatment of psychiatric disorders. In addition to redrawn art, an improved and more...

© 2008 BrightSurf.com